Embera NeuroTherapeutics Overview
- Founded
- 2007
- Status
- Private
- Employees
- 5
- Latest Deal Type
- Series B
- Latest Deal Amount
- $6.13M
- Investors
- 13
Embera NeuroTherapeutics General Information
Description
Provider of medication designed to treat addiction by moderating activity in the stress response system. The company's medication reduces the cravings and loss of control that drive addiction by targeting multiple pathways, to maximize potential efficacy more than either drug used alone, enabling users to abstain from smoking and drug use.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 29 Babe Ruth Drive
- Suite 210
- Sudbury, MA 01776
- United States
+1 (978) 000-0000
Embera NeuroTherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC (Series B) | 01-Aug-2020 | $6.13M | 000.00 | 000.00 | Completed | Clinical Trials - Phase 2 |
| 9. Grant | 26-Jul-2016 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 1 | |
| 8. Later Stage VC (Series B) | 29-Jan-2016 | 00.00 | 000.00 | 0000 | Completed | Clinical Trials - Phase 1 |
| 7. Accelerator/Incubator | 05-Aug-2015 | 0000 | Completed | Generating Revenue | ||
| 6. Later Stage VC (Series A2) | 26-Feb-2015 | 00.000 | 0000 | 000.00 | Completed | Generating Revenue |
| 5. Grant | 01-Jul-2014 | 00.00 | 00.00 | Completed | Generating Revenue | |
| 4. Early Stage VC (Series A2) | 15-Aug-2011 | 00.00 | 00.00 | 00.000 | Completed | Startup |
| 3. Early Stage VC (Series A) | 03-Sep-2008 | 000 | 00.000 | Completed | Startup | |
| 2. Early Stage VC (Series A1) | 25-Aug-2008 | $1.36M | $1.96M | 0000 | Completed | Startup |
| 1. Early Stage VC (Series A) | 23-Jan-2007 | $600K | $600K | Completed | Startup |
Embera NeuroTherapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 00,000,000 | 00.000000 | 00.00 | 00.0 | 00.0 | 00 | 00.0 | 00.00 |
| Series A2 | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A1 | 1,357,100 | $0.001000 | $0.06 | $1 | $1 | 1x | $1 | 3.74% |
Embera NeuroTherapeutics Executive Team (10)
Embera NeuroTherapeutics Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Franz Hefti Ph.D | Self | Board Member | 000 0000 |
| John Beaird | Self | Board Member | 000 0000 |
| Joseph Lovett | Louisiana Funds | Board Member | 000 0000 |
| Ross Barrett JD | BVM Capital | Board Member | 000 0000 |
Embera NeuroTherapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialEmbera NeuroTherapeutics Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Seven Funds | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Keiretsu Forum | Venture Capital | Minority | 000 0000 | 000000 0 | |
| NO/LA Angel Network | Angel Group | Minority | 000 0000 | 000000 0 | |
| Technomark Life Sciences | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Entrepreneurial Accelerator Program | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |